MDxHealth Stock Up 6.0 %
MDXH opened at $2.82 on Thursday. MDxHealth has a fifty-two week low of $2.15 and a fifty-two week high of $8.51. The business has a 50-day moving average of $2.74 and a 200-day moving average of $3.31. The company has a debt-to-equity ratio of 2.17, a current ratio of 2.42 and a quick ratio of 1.19. The company has a market capitalization of $76.96 million, a PE ratio of -1.52 and a beta of 0.30.
MDxHealth’s stock is going to reverse split on the morning of Friday, December 29th. The 1-10 reverse split was announced on Monday, October 2nd. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, December 28th.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in MDXH. Alyeska Investment Group L.P. acquired a new position in shares of MDxHealth during the 1st quarter valued at about $1,944,000. Hood River Capital Management LLC acquired a new position in shares of MDxHealth during the 1st quarter valued at about $1,873,000. Ally Bridge Group NY LLC acquired a new position in shares of MDxHealth during the 1st quarter valued at about $1,620,000. Element Capital Management LLC acquired a new stake in MDxHealth in the 1st quarter valued at approximately $1,386,000. Finally, Perkins Capital Management Inc. grew its holdings in MDxHealth by 382.0% in the 1st quarter. Perkins Capital Management Inc. now owns 408,725 shares of the company’s stock valued at $1,324,000 after buying an additional 323,920 shares during the last quarter. Institutional investors and hedge funds own 20.20% of the company’s stock.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications.
- Five stocks we like better than MDxHealth
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- MarketBeat Week in Review – 11/6 – 11/10
- NYSE Stocks Give Investors a Variety of Quality Options
- Data giants MongoDB and Snowflake just got upgraded
- What is a Stock Market Index and How Do You Use Them?
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.